<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007276</url>
  </required_header>
  <id_info>
    <org_study_id>Lumify Study</org_study_id>
    <nct_id>NCT04007276</nct_id>
  </id_info>
  <brief_title>The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients</brief_title>
  <official_title>The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead&#xD;
      to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure&#xD;
      while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution&#xD;
      0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of&#xD;
      glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye&#xD;
      redness, intraocular pressure, and eyelid position in patients with glaucoma who are already&#xD;
      using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2025</start_date>
  <completion_date type="Anticipated">June 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2030</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each patient will be randomized to receive the study medication in one eye and placebo in the other eye.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>5 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>15 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>30 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Measurement of intraocular pressure using handheld tonometer (TonoPen)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Palpebral fissure height</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Measurement of distance between inner margin of upper and lower eyelids from clinical photographs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye discomfort</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Subjective scoring of ocular discomfort by patient on a 0-10 unit scale (0 = very comfortable, 10 = very uncomfortable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma; Drugs</condition>
  <condition>Droopy Eyelid</condition>
  <condition>Ptosis</condition>
  <condition>Glaucoma, Primary Open Angle</condition>
  <arm_group>
    <arm_group_label>Lumify Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine tartrate ophthalmic solution 0.025%</intervention_name>
    <description>Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.</description>
    <arm_group_label>Lumify Arm</arm_group_label>
    <other_name>Lumify™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sterile balanced saline solution</intervention_name>
    <description>Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Diagnosis of primary open angle glaucoma&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
          -  Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Known allergy or sensitivities to brimonidine&#xD;
&#xD;
          -  No surgery within the past 6 months&#xD;
&#xD;
          -  No history of lid surgery or botox&#xD;
&#xD;
          -  Any other significant ophthalmologic disorder or condition with relevant effect on&#xD;
             ocular redness, IOP, or eyelid position as evaluated by principal investigator&#xD;
&#xD;
          -  Inability to sit comfortably for 30 minutes&#xD;
&#xD;
          -  Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or&#xD;
             phenylephrine dilating drops within 1 week of study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ze Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ze Zhang, MD</last_name>
    <phone>504-988-5831</phone>
    <email>zzhang9@tulane.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheila Lawshe</last_name>
    <phone>504-988-2261</phone>
    <email>slawshe@tulane.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ze Zhang, MD</last_name>
      <phone>504-988-5831</phone>
      <email>zzhang9@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Ze Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

